MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Clinical trials for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) explained in plain language.
Never miss a new study
Get alerted when new MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) trials appear
Sign up with your email to follow new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough prostate cancer
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see how the drug…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 16, 2026 22:28 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (SHR-1701) to targeted radiation (SBRT) can slow the growth of metastatic castration-resistant prostate cancer. About 66 men aged 18-80 whose cancer has spread and stopped responding to hormone therapy will participate. The mai…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New hope for tough prostate cancer: early trial of ACE-232 begins
Disease control Recruiting nowThis early-phase study tests a new drug called ACE-232 in about 67 men with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The main goals are to check the drug's safety, find the best dose, and see early signs it might help con…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New radioactive drug targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug called [225Ac]Ac-AKY-2519 in people with a hard-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The drug targets a protein (B7-H3) on cancer cells to deliver radiation directly to tum…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New drug cocktail aims to stall Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new two-drug combination (gedatolisib plus darolutamide) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to standard hormone therapy. The goal is to find the safest, most effective dose and see if the c…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Celcuity Inc • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug combo trial offers hope for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called pocenbrodib, either by itself or combined with other treatments, in people with a type of advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose and see if it helps shrink tumors or lower PSA lev…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New hope for advanced cancer: experimental drug MHB048C enters human trials
Disease control Recruiting nowThis study tests a new drug called MHB048C in 200 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. Participants receive the drug by IV and are monitored for side effects and tumor re…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for hard-to-treat prostate cancer: drug duo aims to delay progression
Disease control Recruiting nowThis study tests whether the drug talazoparib, alone or combined with enzalutamide, can delay cancer growth in men with a specific type of advanced prostate cancer (mCRPC with HRR mutations) that has worsened after previous treatment with abiraterone. About 126 participants will …
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side e…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: PHASE1 • Sponsor: Orano Med LLC • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New study peers inside cancer to see why some tumors fight back
Knowledge-focused Recruiting nowThis study uses special PET scans to watch how each individual cancer spot (metastasis) in men with advanced prostate cancer responds to treatment. The goal is to understand why some spots shrink while others keep growing, a key reason treatments stop working. About 45 men will b…
Matched conditions: MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)
Phase: NA • Sponsor: Frederic Pouliot • Aim: Knowledge-focused
Last updated May 16, 2026 22:31 UTC